Premium
Cervical cancer screening in the era of HPV vaccination: A review of shifting paradigms in cytopathology
Author(s) -
Barroeta Julieta E.,
AdhikariGuragain Deepti,
Grotkowski Carolyn E.
Publication year - 2017
Publication title -
diagnostic cytopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.417
H-Index - 65
eISSN - 1097-0339
pISSN - 8755-1039
DOI - 10.1002/dc.23737
Subject(s) - medicine , cervical cancer , cytopathology , vaccination , triage , cytology , cervical cancer screening , gynecology , cervical screening , cervical intraepithelial neoplasia , cancer , oncology , pathology , medical emergency
Abstract Significant changes in cervical cancer screening practice, guidelines, and prevention of cervical cancer have taken place in recent years including the raising of initial cervical cancer screening age, changes in frequency of cytology screening, and the adoption of high risk HPV and cytology co‐testing for some patients; the introduction of the bivalent, quadrivalent, and 9‐valent HPV vaccines; and the recent approval of high risk HPV testing as primary screening with the use of cytology as triage in positive cases. This review discusses the significance of primary HPV screening, the impact of HPV vaccination in the prevalence of cervical cancer and its precursors, the interplay between high risk HPV testing and vaccination, and the implications for clinical and cytological management. Future strategies for cervical screening in the post‐vaccination era are also discussed.